H2020 IMI: Futuros Topics
Te informamos de las novedades más interesantes en relación con la Iniciativa de Medicamentos Innovadores (IMI). Ya está publicado el borrador de los futuros topics de las próxima convocatoria 20 de IMI correspondientes al Programa de Trabajo de 2020. Se trata de una convocatoria en dos fases, estando prevista su apertura el 21 de enero de 2020.
Los topics en consideración son los siguientes:
- Early diagnosis, prediction of radiographic outcomes and development of rational, personalised treatment strategies to improve long-term outcomes in Psoriatic Arthritis
- Innovations to accelerate vaccine development and manufacture
- Real-world clinical implementation of liquid biopsy
- Tumour plasticity
- Proton versus photon therapy for oesophageal cancer - a trimodality strategy
- Handling of protein drug products and stability concerns
- Academia and industry united innovation and treatment for tuberculosis (UNITE4TB)
Se trata de un documento preliminar, es posible que se produzcan cambios en los textos e incluso que se posponga o se elimine alguno de los topics.
Potenciales futuros topics
Se ha actualizado la lista de topics que se están considerando para futuras convocatorias, con apertura prevista el 23 de junio de 2020. La discusión de estos topics está todavía en un estado inicial, por lo que pueden cambiar con frecuencia, desparecer o incluirse otros. Los que actualmente están en consideración son los siguientes:
Neurodegeneration and other neuroscience priorities
- Rare neurodegenerative and neurocognitive diseases clinical platform development
- Complement in neurodegenerative diseases
'Pain' portfolio
- Digital endpoints and placebo effect in chronic pain
Infection control including vaccines
- Development of innovative personalized diagnostics and patient-guided therapies for the management of sepsis-induced immune suppression
- Modelling the impact of monoclonal antibodies and vaccines on the reduction of antimicrobial resistance
Big data, digital health, clinical trials and regulatory research
- Data lakes
- Personalised endpoints
- Returning clinical trial data to patients: The proactive return of clinically relevant information to study participants during and after a clinical trial
Oncology
- Microbiome
Translational safety
- Pharmacodynamic drug-drug interaction predictive testing by learning algorithms to enhance safety
- Digital vivarium
Facilitating rare disease therapies (including Advanced Therapy Medical Products) reaching patients in Europe
- Clinical outcomes assessments for rare diseases
- Defragmenting and shortening the path to rare disease diagnosis by using genetic screening and digital technologies
Restricted Call to maximise the impact of IMI2 JU objectives and scientific priorities